Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 21533037 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Ammosova T, et al. (2011) Protein Phosphatase-1 Activates CDK9 by Dephosphorylating Ser175. PLoS One 6, e18985 21533037
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S175-p - CDK9 (human) ▲
Orthologous residues
CDK9 (human): S175‑p, CDK9 iso2 (human): S292‑p, CDK9 (mouse): S175‑p, CDK9 (rat): S175‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, immunoprecipitation, mass spectrometry, mutation of modification site, phosphopeptide mapping
 Relevant cell lines - cell types - tissues:  293T (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
PHOSPHATASE PPP1CA (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE PPP1CA (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
okadaic acid increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, inhibited
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
CCNT1 (human) Induces co-immunoprecipitation
HEXIM1 (human) Disrupts co-immunoprecipitation
 Comments:  CDK9 S175A mutant activates HIV-1 transcription

T186-p - CDK9 (human) ▲
Orthologous residues
CDK9 (human): T186‑p, CDK9 iso2 (human): T303‑p, CDK9 (mouse): T186‑p, CDK9 (rat): T186‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293T (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE PPP1CA (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
okadaic acid increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.